329932-55-0

Basic information

• Product Name: HIF-1alpha/2alpha Inhibitor
• Synonyms: FM19G11;HIF-1alpha/2alpha Inhibitor;[2-oxo-2-(p-tolyl)ethyl] 3-[(2,4-dinitrobenzoyl)amino]benzoate;3-[(2,4-Dinitrobenzoyl)amino]-benzoic acid 2-(4-methylphenyl)-2-oxoethyl ester;HIF-1α/2α Inhibitor IV, FM19G11
• CAS NO: 329932-55-0
• Molecular Formula: C₂₃H₁₇N₃O₈
• Molecular Weight: 463.39638
• Mol File: 329932-55-0.mol
• Article Data: 2

Chemical Properties

• Appearance: off-white to light brown/
• Storage Temp.: 2-8°C
• Solubility: DMSO: ≥40mg/mL
• CAS DataBase Reference: HIF-1alpha/2alpha Inhibitor(CAS DataBase Reference)
• NIST Chemistry Reference: HIF-1alpha/2alpha Inhibitor(329932-55-0)
• EPA Substance Registry System: HIF-1alpha/2alpha Inhibitor(329932-55-0)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 329932-55-0(Hazardous Substances Data)

Usage

Description

HIF-1alpha/2alpha Inhibitor, also known as FM19G11, is a compound that targets and inhibits the hypoxia-inducible factors HIF-1alpha and HIF-2alpha. These factors are crucial for cellular adaptation to low oxygen conditions and are often overexpressed in various cancers, promoting tumor growth and survival. By inhibiting HIF-1alpha/2alpha, FM19G11 can potentially disrupt these processes and have therapeutic effects on cancer cells.

Uses

Used in Pharmaceutical Research:
HIF-1alpha/2alpha Inhibitor is used as a research tool for studying the effects of hypoxia-inducible factors on various cellular processes and their role in cancer development and progression.
Used in Cancer Therapy:
HIF-1alpha/2alpha Inhibitor is used as a potential therapeutic agent for targeting hypoxia-inducible factors in cancer cells, with the aim of disrupting their survival and growth mechanisms.
Used in Ependymal Stem Progenitor Cells (epSPCs) Research:
HIF-1alpha/2alpha Inhibitor is used as a compound to study its effects on the self-renewal and proliferation of ependymal stem progenitor cells (epSPCs) in mice, which can provide insights into the role of HIF factors in stem cell biology.
Used in Glioblastoma (GBM) Research:
HIF-1alpha/2alpha Inhibitor is used to study its effects on the O6-methylguanine DNA-methyltransferase (MGMT) expression in glioblastoma (GBM) cells, which can help understand the role of HIF factors in the development and progression of this aggressive brain cancer.
Used in Melanoma Research:
HIF-1alpha/2alpha Inhibitor is used to study its effects on microphthalmia-associated transcription factor (MITF) expression in melanoma cell lines, which can provide insights into the role of HIF factors in melanoma development and progression.
Used in Drug Delivery Systems:
HIF-1alpha/2alpha Inhibitor is used in combination with gold nanoparticles (NPs) to study the effects of FM19G11-loaded gold nanoparticles on various cellular processes, aiming to improve the delivery, bioavailability, and therapeutic outcomes of the compound in cancer treatment.

Biochem/physiol Actions

FM19G11 is an inhibitor of Hypoxia Inducible Factors α (HIFα), reported to affect self-renewal and differentiation of stem cells. Hypoxia-inducible factors (HIFs) are transcription factors that respond to changes in available oxygen in the cellular environment. Among other functions (like angiogenesis), HIFα proteins affect the self-renewal and the differentiation processes of stem cells. FM19G11 inhibits the HIFα proteins that repress the target genes of the two α subunits, in various tumor cell lines as well as in adult and embryonic stem cell (ESC) models.

Upstream product

• 906131-02-0 3-((2,4-dinitro)benzamido)benzoic acid 
• 619-41-0 4-(bromoacetyl)toluene 
• 99-05-8 meta-aminobenzoic acid 
• 4518-10-9 Methyl 3-aminobenzoate 
• 348600-05-5 methyl 3-((2,4-dinitro)benzamido)benzoate 

Relevant articles and documents

PHARMACEUTICAL COMPOSITION FOR INHIBITING THE TRANSCRIPTION FACTOR INDUCIBLE BY HYPOXIA, MODULATORS OF PATHOLOGICAL PROCESSES OF ANGIOGENESIS, ONCOGENESIS, INFLAMMATION, APOPTOSIS, AND CELLULAR THERAPY

The present invention is included in the field of pharmacology and medical chemistry and relates to novel molecules represented by general formula (I), especially the one called FM19G11, as well as to pharmaceutical compositions containing them. Said pharmacologically optimized compositions are capable of modulating and/or inhibiting the transcription of genes modulated by the hypoxia-inducible transcription factor (HIF) and which are directly and/or indirectly involved in pathological processes related to cancer, inflammation, tissue repair, stem cell differentiation and regenerative therapy. The present invention also relates to a method for the synthesis of said molecules (I) and to the use thereof in the manufacture of a medicament for the treatment of the mentioned pathological processes.